Comprehensive Medication List for Addiction Treatment
Pharmacological treatments are available for opioid, alcohol, tobacco, benzodiazepine, and cannabis use disorders, with the strongest evidence supporting medication-assisted treatment for opioid and alcohol use disorders to reduce morbidity and mortality. 1, 2
Medications by Substance Use Disorder
Opioid Use Disorder (OUD)
Three FDA-approved medications exist for OUD, all of which reduce nonmedical opioid use and risk of overdose death:
Buprenorphine (partial mu-opioid agonist)
- Sublingual buprenorphine alone (Subutex)
- Buprenorphine/naloxone combination (Suboxone) - preferred formulation due to abuse-deterrent properties 1, 3
- Long-acting injectable formulations
- FDA-approved for patients ≥16 years 3
- Longer-term maintenance treatment is superior to brief tapers - associated with lower relapse rates 1, 3
Methadone (full mu-opioid agonist)
- Restricted to federally regulated narcotic treatment programs
- Cannot be prescribed from office-based practices 1
Naltrexone (opioid antagonist)
Alcohol Use Disorder (AUD)
Six medications are approved globally for AUD, with different mechanisms targeting consumption reduction versus abstinence maintenance: 4
For reducing alcohol consumption (first-line):
- Nalmefene (opioid antagonist)
- Naltrexone (oral or extended-release injectable)
For maintaining abstinence (first-line):
- Acamprosate (modulates glutamatergic/GABAergic systems)
Second-line options:
- Disulfiram (aldehyde dehydrogenase inhibitor - aversive therapy)
- Best for highly motivated patients in supervised settings
- Baclofen (GABA-B agonist)
- Particularly useful in liver disease
- Sodium oxybate (GHB precursor)
- For severe AUD or protracted withdrawal syndrome
All FDA-approved AUD medications reduce alcohol use and improve HIV outcomes when combined with antiretroviral therapy 2, 4
Tobacco/Nicotine Use Disorder
Multiple FDA-approved pharmacotherapies exist for tobacco cessation, strongly recommended given excess cardiovascular mortality in people with HIV: 2
- Nicotine replacement therapy (patches, gum, lozenges, inhalers, nasal spray)
- Varenicline (nicotinic receptor partial agonist)
- Bupropion (norepinephrine-dopamine reuptake inhibitor)
Cannabis Use Disorder
Emerging evidence supports:
- Gabapentinoids - may decrease withdrawal symptoms 5
- Cannabinoids (e.g., dronabinol, nabilone) - appear to decrease use and withdrawal symptoms 5
Stimulant Use Disorders (Cocaine, Methamphetamine)
No FDA-approved medications currently exist. 2
Evidence-based approaches include:
- Contingency management (behavioral intervention with financial incentives) - most efficacious treatment, strongly recommended 2
- Emerging pharmacological options under investigation:
Benzodiazepine and Z-Drug Dependence
Pharmacological management focuses on medically supervised withdrawal:
- Gradual dose tapering of the same benzodiazepine
- Cross-tapering to longer-acting benzodiazepines (e.g., diazepam, clonazepam)
- Adjunctive medications for withdrawal symptoms 6
Other Substances
GHB/GBL dependence:
- Baclofen (GABA-B agonist) 6
- Benzodiazepines for acute withdrawal
Gabapentinoid dependence:
- Gradual tapering protocols 6
Critical Implementation Principles
Combination with Behavioral Therapy
Pharmacotherapy should be combined with evidence-based behavioral interventions - the combination is superior to either alone 7:
- Cognitive behavioral therapy (CBT)
- Motivational enhancement therapy
- Contingency management
- Community reinforcement approach
However, pharmacotherapy should NOT be restricted only to patients whose goal is abstinence - even reductions in use translate to substantial decreases in morbidity (cancer, hypertension, cardiovascular disease, HIV transmission) 1, 2
Harm Reduction Services
All patients reporting drug use should be offered: 2
- Naloxone for overdose prevention
- Fentanyl and xylazine test strips
- Safe use education
- Referral to syringe services programs
Treatment Access Considerations
For opioid use disorder specifically:
- As of January 2023, the DEA X-waiver requirement was eliminated for buprenorphine prescribing 3
- New 8-hour training requirement exists for substance use disorder treatment
- Buprenorphine can be initiated in office or at home 3
- Initiation requires patient to be in opioid withdrawal to avoid precipitated withdrawal:
- Short-acting opioids: ~12 hours since last use
- Long-acting opioids/methadone: 48-72 hours since last use
- Fentanyl may require >12 hours 3
Common Pitfalls to Avoid
Do not withhold medications for substance use disorders in patients receiving antiretroviral therapy or hepatitis C treatment - few clinically significant drug interactions exist 2
Do not use brief buprenorphine tapers (medical withdrawal) - associated with high relapse rates; maintenance treatment is indicated 1, 3
Do not delay treatment for co-occurring psychiatric disorders - treat concurrently to maximize outcomes 3
Do not require abstinence before initiating pharmacotherapy - harm reduction is a valid treatment goal 1
For pregnant women with OUD, offer buprenorphine (without naloxone) or methadone - associated with improved maternal outcomes 8
Polysubstance Use Considerations
SUD severity increases with number of substances used - among those with ≥5 substances, 44.4% have severe SUD 9. Comprehensive assessment across all substances is essential, particularly with stimulant or polysubstance use patterns 9.